Indivior Pharmaceuticals, Inc. — Earnings

Most recent reported period: FY2026 (Q1) (filed for period ending 2026-03-31) · sourced from SEC EDGAR

Next earnings (estimated): Tue, June 30, 2026 ~60 days away. Anchored to latest quarter-end + 91 days. Analyst-confirmed dates land in a follow-up wave.
YoY = vs same quarter prior year (seasonality-adjusted)

Recent earnings · last 8 quarters

Quarter endRevenueYoYNet IncomeYoYOp. Margin
2026-03-31$317M↑+19.2%$89M↑+89.4%43.2%
2025-12-31$358M↑+19.7%$102M↑+385.7%22.6%
2025-09-30$314M↑+2.3%$42M↑+90.9%13.7%
2025-06-30$302M↑+1.0%$18M↑+118.6%23.8%
2025-03-31$266M↓-6.3%$47M↓-23.0%24.8%
2024-12-31$299M$21M15.4%
2024-09-30$307M$22M11.4%
2024-06-30$299M$-97M-39.5%

Analyst consensus estimates (EPS / Revenue) and implied move from options will land in a follow-up wave. For now, YoY-vs-prior-year-quarter is the surprise proxy.

Last earnings · FY2026 (Q1)

Revenue
$317M
↑+19.2% +$51M YoY
Net Income
$89M
↑+89.4% +$42M YoY

Earnings surprise · last 8 quarters

YoY % change · proxy for analyst surprise until estimates land

EPS history · last 10 fiscal years

diluted, GAAP, annual

Note: EPS reflects WEIGHTED-AVERAGE diluted shares for each fiscal year. Pre-stock- split values can blow up the early bars if SEC's XBRL data isn't split-adjusted — flagged as a known limitation; cumulative split-adjustment is a follow-up.

Margin trends · 12 quarters

margin trajectory tells the operating-leverage story
Gross Margin↑+4.3pts
87.4%
Operating Margin↑+18.4pts
43.2%
Net Margin↑+10.4pts
28.1%

Go deeper